Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer
Completed · Phase 1
Conditions studied: Gastric Cancer, Precancerous Condition
In brief
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying how well cetuximab works in treating patients with Ménétrier disease at high risk of developing stomach cancer.
Key facts
- Study ID
- NCT00477880
- Run by
- Vanderbilt University
- People needed
- 9
- Starts
- 2001-04-01
- Expected to finish
- 2010-09-01
- Last updated by the study team
- 2017-01-10
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center at Franklin — Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.